Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

133.70 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abbott Laboratories

< Previous 1 2 3 4 5 6 Next >
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
Via Get News
Topics Death Economy
“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”
Via AB Newswire
MarketBeat Week in Review – 10/14 - 10/18
Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election. 
Via MarketBeat
Topics Artificial Intelligence Economy
Abbott Laboratories (NYSE: ABT) Records 52-Week High Friday Morning
Via Investor Brand Network
Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results align with the trend. 
Via MarketBeat
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases 
Via MarketBeat
Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally
Medtronic's Q1 FY2025 results were driven by its diabetes products, and new offerings in development or pending FDA approval could fuel future performance. 
Via MarketBeat
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
Intuitive Surgical is an AI stock that you can buy and hold forever. Its business is health care; it makes profits, and health care is growing 
Via MarketBeat
Topics Artificial Intelligence
Why This Leading Health Stock is a Buy No Matter the Market Move
Abbott's reliable dividend is more reliable than ever and is expected to continue growing at a high-single to low-double-digit CAGR. 
Via MarketBeat
U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist
From Financial Buzz Media
Via GlobeNewswire
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:ABT),(NASDAQ:CELH),(NASDAQ:MNST),(NYSE:BRBR) EQNX::TICKER_END 
Via FinancialNewsMedia
Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important
From FN Media Group LLC
Via GlobeNewswire
Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
Via AB Newswire
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook. 
Via MarketBeat
Abbott Laboratories Outlook is Healthy: Buy the Dip
Abbott Laboratories had a steady quarter, producing growth, better-than-expected earnings, and raising the guidance. Analysts see the stock moving higher. 
Via MarketBeat
Johnson & Johnson is as Cheap as it’s Going to Get
Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely. 
Via MarketBeat
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People 
Via MarketBeat
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
Via AB Newswire
Topics Death
Medtronic is a Dividend Aristocrat That Keeps Gaining
A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector 
Via MarketBeat
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
4 med tech stocks with improving prognosis for 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025. 
Via MarketBeat
Abbott Laboratories on track for new highs in 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact. 
Via MarketBeat
Johnson & Johnson's stock price is at a critical turning point
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech. 
Via MarketBeat
Topics Intellectual Property
Medtronic receives FDA approval for deep brain stimulation system
Medical device maker Medtronic PLC (NYSE: MDT) received U.S. FDA approval for its implantable medical device called the Percept PC Deep Brain Stimulation (DBS) 
Via MarketBeat
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
From Tandem Diabetes Care, Inc.
Via Business Wire
AbbVie continues shopping spree with biotech buyout
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend. 
Via MarketBeat
Medtronic: oversold, overextended high yield reversal in play
The reversal in Medtronic has been brewing for some time but is gaining traction after strong second quarter earnings that came with improved guidance 
Via MarketBeat
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.